In last trading session, Avenue Therapeutics Inc. (NASDAQ:ATXI) saw 0.26 million shares changing hands with its beta currently measuring -0.57. Company’s recent per share price level of $1.46 trading at $0.03 or 2.10% at ring of the bell on the day assigns it a market valuation of $7.26M. That closing price of ATXI’s stock is at a discount of -1739.04% from its 52-week high price of $26.85 and is indicating a premium of 4.79% from its 52-week low price of $1.39. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.78 million shares which gives us an average trading volume of 4.33 million if we extend that period to 3-months.
Avenue Therapeutics Inc. (NASDAQ:ATXI) trade information
Upright in the green during last session for gaining 2.10%, in the last five days ATXI remained trading in the red while hitting it’s week-highest on Thursday, 11/17/22 when the stock touched $1.46 price level, adding 14.62% to its value on the day. Avenue Therapeutics Inc.’s shares saw a change of -89.28% in year-to-date performance and have moved -18.44% in past 5-day. Avenue Therapeutics Inc. (NASDAQ:ATXI) showed a performance of -47.29% in past 30-days. Number of shares sold short was 13550.0 shares which calculate 0 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of $180.00 to the stock, which implies a rise of 99.19% to its current value. Analysts have been projecting $180.00 as a low price target for the stock while placing it at a high target of $180.00. It follows that stock’s current price would drop -12228.77% in reaching the projected high whereas dropping to the targeted low would mean a loss of -12228.77% for stock’s current value.
Avenue Therapeutics Inc. (ATXI) estimates and forecasts
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 10.40% during past 5 years.
Avenue Therapeutics Inc. is more likely to be releasing its next quarterly report on August 14 and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.
Avenue Therapeutics Inc. (NASDAQ:ATXI)’s Major holders
Insiders are in possession of 9.72% of company’s total shares while institution are holding 7.70 percent of that, with stock having share float percentage of 8.52%. Investors also watch the number of corporate investors in a company very closely, which is 7.70% institutions for Avenue Therapeutics Inc. that are currently holding shares of the company. Vanguard Group, Inc. (The) is the top institutional holder at ATXI for having 8771.0 shares of worth $35430.0. And as of Jun 29, 2022, it was holding 0.59% of the company’s outstanding shares.
The second largest institutional holder is Renaissance Technologies, LLC, which was holding about 8293.0 shares on Jun 29, 2022. The number of shares represents firm’s hold over 0.56% of outstanding shares, having a total worth of $33499.0.
On the other hand, Vanguard Extended Market Index Fund and Fidelity Extended Market Index Fund are the top two Mutual Funds which own company’s shares. As of Jun 29, 2022, the former fund manager was holding 8335.0 shares of worth $33669.0 or 0.56% of the total outstanding shares. The later fund manager was in possession of 3530.0 shares on Jun 29, 2022, making its stake of worth around $14259.0 in the company or a holder of 0.24% of company’s stock.